» Articles » PMID: 22013105

Exenatide Exerts a Potent Antiinflammatory Effect

Overview
Specialty Endocrinology
Date 2011 Oct 21
PMID 22013105
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Our objective was to determine whether exenatide exerts an antiinflammatory effect.

Research Design And Methods: Twenty-four patients were prospectively randomized to be injected sc with either exenatide 10 μg twice daily [n = 12; mean age = 56 ± 3 yr; mean body mass index = 39.8 ± 2 kg/m(2); mean glycosylated hemoglobin (HbA1c) = 8.6 ± 0.4%] or placebo twice daily (n = 12; mean age = 54 ± 4 yr; mean body mass index = 39.1 ± 1.6 kg/m(2); mean HbA1c = 8.5 ± 0.3%) for 12 wk. Fasting blood samples were obtained at 0, 3, 6, and 12 wk. Blood samples were also collected for up to 6 h after a single dose of exenatide (5 μg) or placebo.

Results: Fasting blood glucose fell from 139 ± 17 to 110 ± 9 mg/dl, HbA1c from 8.6 ± 0.4 to 7.4 ± 0.5% (P < 0.05), and free fatty acids by 21 ± 5% from baseline (P < 0.05) with exenatide. There was no weight loss. There was a significant reduction in reactive oxygen species generation and nuclear factor-κB binding by 22 ± 9 and 26 ± 7%, respectively, and the mRNA expression of TNFα, IL-1β, JNK-1, TLR-2, TLR-4, and SOCS-3 in mononuclear cells by 31 ± 12, 22 ± 10, 20 ± 11, 22 ± 9, 16 ± 7, and 31 ± 10%, respectively (P < 0.05 for all) after 12 wk of exenatide. After a single injection of exenatide, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive oxygen species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression, 18 ± 7% in JNK-1 expression, 24 ± 12% in TLR-4 expression, and 23 ± 11% in SOCS-3 expression (P < 0.05 for all). The plasma concentrations of monocyte chemoattractant protein-1, matrix metalloproteinase-9, serum amyloid A, and IL-6 were suppressed after 12 wk exenatide treatment by 15 ± 7, 20 ± 11, 16 ± 7, and 22 ± 12%, respectively (P < 0.05 for all).

Conclusions: Exenatide exerts a rapid antiinflammatory effect at the cellular and molecular level. This may contribute to a potentially beneficial antiatherogenic effect. This effect was independent of weight loss.

Citing Articles

Polyethylene Glycol Loxenatide Accelerates Diabetic Wound Healing by Downregulating Systemic Inflammation and Improving Endothelial Progenitor Cell Functions.

Ding Z, Yang C, Zhai X, Xia Y, Liu J, Yu M Int J Mol Sci. 2025; 26(5).

PMID: 40076985 PMC: 11901084. DOI: 10.3390/ijms26052367.


Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD.

Ahmadi A, Gamboa J, Norman J, Enkhmaa B, Tucker M, Bennett B Clin J Am Soc Nephrol. 2024; 20(1):12-22.

PMID: 39480994 PMC: 11737449. DOI: 10.2215/CJN.0000000000000566.


Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.

Koychev I, Reid G, Nguyen M, Mentz R, Joyce D, Shah S Alzheimers Res Ther. 2024; 16(1):212.

PMID: 39358806 PMC: 11448378. DOI: 10.1186/s13195-024-01573-x.


The weight reduction mediated by anti-obesity medication and the cardiovascular outcome.

Guo Y, Lin C, Cai X, Wu H, Yan J, Li Z iScience. 2024; 27(10):110867.

PMID: 39319264 PMC: 11419803. DOI: 10.1016/j.isci.2024.110867.


The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.

Kantreva K, Katsaounou P, Saltiki K, Trakada G, Ntali G, Stratigou T Endocrine. 2024; 87(2):378-388.

PMID: 39289244 DOI: 10.1007/s12020-024-04033-6.


References
1.
Galis Z, Sukhova G, Lark M, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6):2493-503. PMC: 330083. DOI: 10.1172/JCI117619. View

2.
Timmers L, Henriques J, de Kleijn D, DeVries J, Kemperman H, Steendijk P . Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53(6):501-10. DOI: 10.1016/j.jacc.2008.10.033. View

3.
Holz G, Chepurny O . Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem. 2003; 10(22):2471-83. PMC: 2911578. DOI: 10.2174/0929867033456648. View

4.
Edwards C, Stanley S, Davis R, Brynes A, Frost G, Seal L . Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281(1):E155-61. DOI: 10.1152/ajpendo.2001.281.1.E155. View

5.
Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton D . SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001; 276(51):47944-9. DOI: 10.1074/jbc.M104602200. View